Glycation of alpha-synuclein enhances aggregation and neuroinflammatory responses

Eftychia Vasili,Annekatrin Konig,Mohammed Al-Azzani,Clara Bosbach,Luisa Maria Gatzemeier,Ana Chegao,Hugo Vicente Miranda,Daniel Erskine,Tiago Outeiro
DOI: https://doi.org/10.1101/2024.06.27.600956
2024-07-02
Abstract:The risk of developing Parkinson's disease (PD) is elevated in people with type 2 diabetes, but the precise molecular pathways underlying this connection are still unclear. One hypothesis is that glycation, a non-enzymatic family of reactions between glycating agents, such as reducing sugars or reactive dicarbonyls, and specific amino acids, such as lysines and arginines, may alter proteostasis and trigger pathological alterations. Glycation of alpha-synuclein (aSyn), a central player in PD pathology, causes profound changes in the aggregation process of aSyn. Methylglyoxal (MGO), a strong glycating agent, induces the formation of pathological inclusions enriched in phosphorylated aSyn on serine 129 (pS129). In addition, we found that neuroinflammatory responses are enhanced by MGO-mediated aSyn glycation. Using novel polyclonal antibodies developed towards specific MGO-glycated aSyn residues, we confirmed the occurrence of glycated aSyn both in vitro as well as in animal and in human brain tissue. In total, our findings shed light into the interplay between glycation, PD, and type 2 diabetes, potentially paving the way for the development of novel therapeutic strategies targeting these intertwined conditions.
Neuroscience
What problem does this paper attempt to address?
This paper primarily explores the association between diabetes (particularly type 2 diabetes) and Parkinson's disease (PD), focusing on a non-enzymatic reaction called glycation. The study found that glycation enhances the aggregation of α-synuclein (aSyn) and neuroinflammatory responses, which are key pathological factors in Parkinson's disease. Specifically, methylglyoxal (MGO), a potent glycating agent, induces the formation of phosphorylated aSyn pathological inclusions and promotes neuroinflammation. By developing polyclonal antibodies targeting specific MGO-glycated aSyn residues, researchers have confirmed the presence of glycated aSyn in vitro, in vivo, and human brain tissues. These findings reveal the interplay between glycation, Parkinson's disease, and type 2 diabetes, potentially providing a new avenue for developing novel therapeutic strategies for both diseases.